Montanide Isa-51
Recurrent Prostate Cancer
University Hospital TuebingenPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Recurrent Prostate Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
azd0530 National Cancer Institute (NCI) | Phase 2 | B |
Rebimastat National Cancer Institute (NCI) | Phase 2 | B |
Procarbazine National Cancer Institute (NCI) | Phase 2 | B |
Lapatinib UNC Lineberger Comprehensive Cancer Center | Phase 2 | B |
Bms-907351 University of Utah | Phase 2 | B |
View all 33 →
Same molecule, other indications
Montanide Isa-51 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →